Literature DB >> 23363249

Best treatment practices for pachyonychia congenita.

I Goldberg1, D Fruchter, A Meilick, M E Schwartz, E Sprecher.   

Abstract

BACKGROUND: Numerous therapeutic modalities have been proposed to treat the manifestations of pachyonychia congenita (PC). While research hopes lie with molecular therapies, patients are in need of answers regarding the efficacy of conventional treatments. AIM OF THE STUDY: To determine patients' experience and preferences regarding conventional treatments for PC.
METHODS: The study population included 120 PC patients from 20 countries. The study was based on a patient survey developed by physicians and researchers from the International Pachyonychia Congenita Consortium and conducted via the internet. Using an effectiveness scale of 1 to 5, the patients were asked to grade treatments for different manifestations, including keratoderma, cysts, follicular hyperkeratosis, fingernail and toenail involvement.
RESULTS: Patients reported surgical treatments being most effective for cysts and mechanical treatments the most effective conventional therapeutic approach for all other investigated manifestations. The other conventional medical treatments were found to be non-effective to only slightly effective. Among patients with keratoderma, older people were more likely to report beneficial effect from mechanical treatments (P = 0.04), topical retinoids (P = 0.04) and topical steroids (P = 0.02). Likewise, females were more inclined to report filing and grinding beneficial than males (P = 0.02). Finally, carriers of KRT16 and KRT6a were more likely to benefit from keratolytics than carriers of mutations in KRT17 (P = 0.04).
CONCLUSIONS: None of the currently available therapeutic options for PC are ideal, although they provide some relief, with mechanical/surgical options being preferred over medical therapies. These results emphasize the need for more efficient and targeted therapies.
© 2013 The Authors Journal of the European Academy of Dermatology and Venereology © 2013 European Academy of Dermatology and Venereology.

Entities:  

Mesh:

Year:  2013        PMID: 23363249     DOI: 10.1111/jdv.12098

Source DB:  PubMed          Journal:  J Eur Acad Dermatol Venereol        ISSN: 0926-9959            Impact factor:   6.166


  7 in total

Review 1.  Pathophysiology of pachyonychia congenita-associated palmoplantar keratoderma: new insights into skin epithelial homeostasis and avenues for treatment.

Authors:  A G Zieman; P A Coulombe
Journal:  Br J Dermatol       Date:  2019-07-24       Impact factor: 9.302

2.  First Report of Pachyonychia Congenita Type PC-K6a in the Romanian Population.

Authors:  Anca Chiriac; Cristina Rusu; Alina Murgu; Anca E Chiriac; Neil J Wilson; Frances J D Smith
Journal:  Maedica (Buchar)       Date:  2017-06

3.  Treatment of Painful Palmoplantar Keratoderma Related to Pachyonychia Congenita Using EGFR Inhibitors.

Authors:  Céline Greco; Anne-Charlotte Ponsen; Stéphanie Leclerc-Mercier; Joël Schlatter; Salvatore Cisternino; Claude Boucheix; Christine Bodemer
Journal:  Biomedicines       Date:  2022-04-03

4.  Keratin 16 regulates innate immunity in response to epidermal barrier breach.

Authors:  Juliane C Lessard; Sylvia Piña-Paz; Jeremy D Rotty; Robyn P Hickerson; Roger L Kaspar; Allan Balmain; Pierre A Coulombe
Journal:  Proc Natl Acad Sci U S A       Date:  2013-11-11       Impact factor: 11.205

5.  Oxidative stress and dysfunctional NRF2 underlie pachyonychia congenita phenotypes.

Authors:  Michelle L Kerns; Jill M C Hakim; Rosemary G Lu; Yajuan Guo; Andreas Berroth; Roger L Kaspar; Pierre A Coulombe
Journal:  J Clin Invest       Date:  2016-05-16       Impact factor: 14.808

6.  Distinctions in the Management, Patient Impact, and Clinical Profiles of Pachyonychia Congenita Subtypes.

Authors:  Albert G Wu; Shari R Lipner
Journal:  Skin Appendage Disord       Date:  2021-02-05

7.  Pachyonychia Congenita in a Toddler.

Authors:  Max Mandelbaum; Jerry W Chao; Gary F Rogers
Journal:  Plast Reconstr Surg Glob Open       Date:  2017-05-16
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.